Bold Eagle Acquisition Corp.

# Signal Note: Driehaus Capital Initiates BEAGR Position Growth-focused Driehaus's $7.6M entry into Bold Eagle suggests conviction in an upcoming SPAC merger target in biotech/healthcare. Without disclosed merger details, the position size (~1.9M shares) indicates moderate conviction rather than core allocation, warranting monitoring for merger announcement and target's clinical/regulatory catalysts. Typical SPAC timelines suggest material news within 6-12 months that could clarify therapeutic focus and de-SPAC timing.